March 15 (Reuters) - Advisers to the U.S. Food and Drug
Administration on Friday voted in favor of allowing the use of
Bristol Myers Squibb's ( BMY ) cell therapy as an earlier
treatment for a type of blood cancer.
The panel voted 8-3 in favor that benefits of Bristol's
Abecma outweighed the risks of the therapy when given as an
earlier treatment.